PSA density improves prediction of prostate cancer

Canadian Journal of Urology

Volumn 21, Issue 3, 2014, Pages 7312-7321

  Verma, Ashok ^a   St Onge, Jennifer ^a   Dhillon, Kam ^a   Chorneyko, Anita ^a  

^a REGINA QU APPELLE HEALTH REGION   (Canada)

Author keywords

Aggressive cancer; Prostate volume; Prostate specific antigen; PSA density

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; TUMOR MARKER;

AGED; BIOPSY; BLOOD; DIGITAL RECTAL EXAMINATION; ECHOGRAPHY; EVALUATION STUDY; HUMAN; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PROSTATE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL;

AGED; BIOPSY; DIGITAL RECTAL EXAMINATION; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 84903976136     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Fowler Jr. FJ, Barry MJ, Walker-Corkery B et al. The impact of a suspicious prostate biopsy on patients' psychological, socio-behavioral, and medical care outcomes. J Gen Intern Med 2006;21(7):715-721.
2. Etzioni R, Cha R, Feuer EJ, Davidov O. Asymptomatic incidence and duration of prostate cancer. Am J Epidemiol 1998;148(8):775-785.
3. Draisma G, Etzioni R, Tsodikov A et al. Lead time and overdiagnosis in prostate-specific antigen screening: Importance of methods and context. J Natl Cancer Inst 2009;101(6):374-383.
4. Sanda MG, Dunn RL, Michalski J et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008;358(12):1250-1261.
5. Andriole GL, Crawford ED, Grubb III RL et al. PLCO Project Team, Mortality results from a randomized prostate cancer screening trial. N Engl J Med 2009;360(17):1310-1319.
6. Schröder FH, Hugosson J, Roobol MJ et al. Auvinen; ERSPC Investigators, Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009;360(13):1320-1328.
7. Carter HB, Morrell CH, Pearson JD et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res 1992;52(12):3323-3328.
8. Carter HB, Ferrucci L, Kettermann A et al. Detection of lifethreatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst 2006;98(21):1521-1527.
9. Catalona WJ, Partin AW, Slawin KM et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: A prospective multicenter clinical trial. JAMA 1998;279(19):1542-1547.
10. Sokoll LJ, Chan DW, Mikolajczyk SD et al. Proenzyme PSA for the early detection of prostate cancer in the 2.5-4.0 ng/ml total PSA range: Preliminary analysis. Urology 2003;61(2):274-276.
11. Kundu SD, Roehl KA, Yu X et al. Prostate specific antigen density correlates with features of prostate cancer aggressiveness. J Urol 2007;177(2):505-509.
12. Brassell SA, Kao TC, Sun L, Moul JW. Prostate-specific antigen versus prostate-specific antigen density as predictor of tumor volume, margin status, pathologic stage, and biochemical recurrence of prostate cancer. Urology 2005;66(6):1229-1233.
13. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: Prediction, detection and monitoring. Nat Rev Cancer 2008;8(4):268-278.
14. Wolff JM, Boeckmann W, Effert PJ, Handt S, Jakse G. Evaluation of patients with diseases of the prostate using prostate-specific antigen density. Br J Urol 1995;76(1):41-46.
15. Catalona WJ, Southwick PC, Slawin KM et al. Comparison of percent free PSA, PSA density, and age-specific PSA cut-offs for prostate cancer detection and staging. Urology 2000;56(2):255-260.
16. Taneja SS, Hsu EI, Cheli CD et al. Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. Urology 2002;60(4 Suppl 1):10-17.
17. Aslan G, Irer B, Kefi A, Celebi I, Yorukoglu K, Esen A. The value of PSA, free-to-total PSA ratio and PSA density in the prediction of pathologic stage for clinically localized prostate cancer. Int Urol Nephrol 2005;37(3):511-514.
18. Radwan MH, Yan Y, Luly JR et al. Prostate-specific antigen density predicts adverse pathology and increased risk of biochemical failure. Urology 2007;69(6):1121-1127.
19. Thong AE, Shikanov S, Katz MH et al. A single microfocus (5% or less) of Gleason 6 prostate cancer at biopsy-can we predict adverse pathological outcomes? J Urol 2008;180(6):2436-2440.
20. Saema A, Kochakarn W, Lertsithichai P. PSA density and prostate cancer detection. J Med Assoc Thai 2012;95(5):661-666.
21. Zlotta AR, Djavan B, Petein M, Susani M, Marberger M, Schulman CC. Prostate specific antigen density of the transition zone for predicting pathological stage of localized prostate cancer in patients with serum prostate specific antigen less than 10 ng/ml. J Urol 1998;160(6 Pt 1):2089-2095.
22. Sfoungaristos S, Perimenis P. PSA density is superior than PSA and Gleason score for adverse pathologic features prediction in patients with clinically localized prostate cancer. Can Urol Assoc J 2012;6(1):46-50.
23. Oh JJ, Hong SK, Lee JK et al. Prostate-specific antigen vs. prostate-specific antigen density as a predictor of upgrading in men diagnosed with Gleason 6 prostate cancer by contemporary multicore prostate biopsy. BJU Int 2012;110(11 Pt B):E494-E499.
24. Magheli A, Hinz S, Hege C et al. Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. J Urol 2010;183(1):126-131.
25. Freedland SJ, Kane CJ, Presti JC et al. Comparison of preoperative prostate specific antigen density and prostate specific antigen for predicting recurrence after radical prostatectomy results from the SEARCH data base. J Urol 2003;169(30):969-973.
26. Luboldt HJ, Schindler JF, Rubben H. Age-specific references ranges for prostate-specific antigen as a marker for prostate cancer. EAU-EBU Update Series 2007;5:38-48.
27. Allan RW, Sanderson, H, Epstein JI. Correlation of minute (0.5 MM or less) focus of prostate adenocarcinoma on needle biopsy with radical prostatectomy specimen: role of prostate specific antigen density. J Urol 2013;170(2 Pt 1):370-372.
28. Nong S, Wen D, Fan C. The relationship of PSA, PSAD and clinicopathological stage in patients with prostate cancer. Chin Clin Oncol 2007;4(5):318-321.
29. Zentner PG, Pao LK, Benson MC, McMahon DJ, Schiff PB. Prostate-specific antigen density: a new prognostic indicator for prostate cancer. Int J Radiat Oncol Biol Phys 1993;27(1):47-58.
30. Ou YC, Chen JT, Yang CR et al. Preoperative prediction of extracapsular tumor extension at radical retropubic prostatectomy in Taiwanese patients with T1c prostate cancer. Jpn J Clin Oncol 2002;32(5):172-176.
31. Jones TD, Koch MO, Bunde PJ et al. Is prostate specific antigen (PSA) density better than the preoperative PSA level in predicting early biochemical recurrence of prostate cancer after radical prostatectomy? BJU Int 2006;97(3):480-484.
32. Epstein JI, Chan DW, Sokoll LJ et al. Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 1998;160(6 Pt 2):2407-2411.